Vector Science & Therapeutics names Russell Starr as president

Vector Science & Therapeutics Corp. (TSXV: PAIN) has appointed Russell Starr as president, effective Oct. 5, 2026. Bill Jackson continues in his role as chief executive officer, according to a company press release.

Starr has elected to receive his full salary in common shares of the company, subject to approval from the TSX Venture Exchange. He was also granted 1,500,000 stock options with a five-year term and an exercise price of $1.65. The options will vest when the company's stock reaches CAD $3.50, $4.50, and $5.50, respectively, based on a 10-day volume-weighted average price for each target.

Starr has previously held senior executive roles at multiple public companies and has been involved in raising over $2 billion for public equities. Any incentive securities granted to him will be performance-based.

"I've been deeply invested in Vector's mission since day one, and I'm honored to take on this role at such a pivotal moment for the Company," Starr said. "I look forward to working alongside Bill and the rest of the team to help Vector scale now that it is producing pharma-grade peptides."

Vector Science & Therapeutics is a medical technology company focused on drug delivery technology and pharma-grade peptide manufacturing for the sports medicine, regenerative medicine, and pain management markets. The company is headquartered in Mequon, Wisconsin.

You May Also Be Interested In

• SeaStar Medical CMO named 2026 Combat Nephrology Award recipient
• XTI Aerospace names Unusual Machines CEO as board chairman
• FDA expands Anktiva approval to include papillary-only bladder cancer